Ocular Therapeutix(US:OCUL) ZACKS·2025-08-05 13:25Financial Performance - Ocular Therapeutix reported a quarterly loss of $0.39 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.35, and compared to a loss of $0.24 per share a year ago, indicating a decline in performance [1] - The company posted revenues of $13.46 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 0.7%, and down from $16.44 million in the same quarter last year [2] - Over the last four quarters, Ocular Therapeutix has not surpassed consensus EPS estimates and has topped revenue estimates only once [2] Stock Performance - Ocular Therapeutix shares have increased by approximately 44.6% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.6% [3] - The stock currently holds a Zacks Rank 5 (Strong Sell), indicating expectations of underperformance in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.34 on revenues of $14.99 million, and for the current fiscal year, it is -$1.42 on revenues of $56.55 million [7] - The estimate revisions trend for Ocular Therapeutix was unfavorable ahead of the earnings release, which may impact future stock movements [6] Industry Context - The Medical - Drugs industry, to which Ocular Therapeutix belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a relatively strong industry performance [8] - Another company in the same industry, Plus Therapeutics, is expected to report a quarterly loss of $0.09 per share, reflecting a year-over-year change of +87.3%, with revenues projected to be $1.7 million, up 32.8% from the previous year [9]